Company Dynamics Update
On April 16, 2025, the Dongtou District People’s Government announced the environmental protection acceptance for Zhejiang Chengyi Pharmaceutical Co., Ltd.’s (Chengyi Pharma) technical renovation project, which includes the production of 80 t/a acetylcysteine, 1,000kg torasemide, and 200kg vitamin K1 active pharmaceutical ingredients (API).
Project Overview and Investment Details
The project is located in Chengyi Pharma’s existing factory area within the Dongtou District Health Industry Park. Key details include:
- Total Investment: USD 0.28 million (RMB 2.00 million)
- Production Capacity Upon Completion:
- 80 tons per annum (t/a) of acetylcysteine
- 1,000 kilograms of torasemide
- 200 kilograms of vitamin K1 API
The project will utilize mature technologies and processes, installing internationally advanced, GMP-compliant equipment such as reaction kettles, centrifuges, and double-cone vacuum dryers sourced domestically.
Product Applications and Market Prospects
- Acetylcysteine: Used primarily in the treatment of respiratory diseases by breaking down mucus.
- Torasemide: A potent diuretic for managing edema and hypertension.
- Vitamin K1: Essential for treating hypoprothrombinemia and preventing neonatal bleeding, with high efficacy and minimal side effects.
The strong clinical relevance and broad market prospects of these products are expected to enhance Chengyi Pharma’s competitiveness, particularly in the growing global demand for APIs addressing respiratory, cardiovascular, and neonatal health needs.
Note: Following the implementation of the new project, Chengyi Pharma will cancel its previously approved 20 t/a famciclovir project.
Company Background
Zhejiang Chengyi Pharmaceutical Co., Ltd. is a well-established pharmaceutical enterprise specializing in the production of APIs, intermediates, and healthcare ingredients. The company is recognized for its adherence to high manufacturing standards and its focus on respiratory, cardiovascular, and specialty therapeutic areas.
Industry Outlook
As global demand for high-quality APIs continues to rise, particularly for respiratory and neonatal care, Chengyi Pharma’s strategic investment in its production capabilities positions it well for future growth. The shift toward technologically advanced, environmentally compliant manufacturing further aligns with China’s evolving pharmaceutical sector regulations.
Empower Your Strategy with China Informatics
Trust China Informatics for:
- Verified news and project reports on China’s pharmaceutical expansions and approvals.
- Actionable insights into API production upgrades and regulatory shifts.
- Industry-focused intelligence to guide manufacturing investments and market positioning strategies.
Stay a step ahead with intelligence tailored for leaders in health and life sciences. Connect with China Informatics today.
